Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers

The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.

Hani Goodarzi, Kevan Shokat, and Johnny Yu are the UCSF co-founders. Congratulations to them all!

More